The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Great find Dr.A, thanks for sharing!
Thanks for the info Telephoneman. I wasn't looking to cause any controversy with the term, was just looking for something to use that clearly differentiated between one unit and possibly many in the the same building like a plant. And all the stages of the process remind me a little of the game mouse trap, that's all. Chopper's DMG unit is more fitting.
Has anyone got more details on the royalty payments from licenees to PHE? I know peel have agreed £500k per annum per mouse trap, and it sounds like HUI will be 500k EUR, but when are the payments due? I.e when Peel signed up for 11, do they start paying for each mouse trap individually when it comes online?
And for the deposits, is this tending to be a specific amount paid for each mouse trap or is it just a negotiation per contract?
Yeah this is my biggest concern too. The rug gets pulled before you've had a chance to multibag. I value each rerate even more! Just hope there are a few more before someone swoops in.
I bought into PHE back in March 2018 with a £1000 I had in my ISA. It was at 0.58p and I'm pretty sure even at that price I was under water for quite a while. But the concept to me was just incredible, being able to turn muck into gold. Paid on the way in and paid on the way out, what everyone dreams of. But obviously there are still massive risks in actually implementing the plan, and there are so many AIM companies out there with a great idea that ultimately fail. This ones really does look capable of going all the way though.
I've held onto to every single share and I'm not planning to sell them now! Today it's become my very first 10x bagger! Onwards and upwards! Good luck all!
Here's the article, so everyone can read it ...
At every step the last few days have seen Powerhouse Energy (PHE) show everything that is wrong with life among the dregs of the AIM Casino. Today a new chapter but as a reminder....
Powerhouse, which has sod all cash, is soon to merge with technically insolvent waste2tricity, a firm run by disgraced former Tory MP Tim Yeo. The combination will have to raise fresh cash within months to avoid a crash landing in tits up alley.
Notwithstanding this, the Sith Lord Zak Mir, formerly on the payroll at wastre2tricity and possibly Powerhouse, not that he declared either ramped the shares with ludicrous Leni-maths style “analysis” pumping the stock as hard as he could. Was he just being a Good German (again) or simply an innumerate buffoon?
Peter Brailey explains the joke valuation in full HERE.
Today we see the shares off by almost 8% as just over 2 million warrants have been exercised at 0.5p. the fall suggests the spivs exercising may not be wating until the shares are admitted on 9 June to sell. This exercise will bring in £10,000 for – running on vapours Powerhouse – and with the shares at 2.6p to sell will see the spivs making c£41,000.
There have been a stream of 0.5p warrants exercised over the past few months as the shares have been ramped. This appears to be the legacy of a placing last summer at 0.5p with associated warrants organised by the scholars and gentlemen at brokers Turner Pope. And that is the way the AIM casino operates: issues shares at a steep discount to insiders (with no Primary Bid option) . allow them to flip and make a cracking turn. And on the off chance the shares fly they can then flip their warrants and make an even bigger profit.
Suffice to say, ahead of the next warrant exercise and then the next placing the shares remain utterly overvalued.
Is the website in my post below
Are at it again...
https://www.*************.com/views/49302/powerhouse-energy-the-legacy-of-bucket-shop-placings
Although if the levee breaks, I'm gonna eating tea for one coz my baby's gonna leave me!
Just took the opportunity to double up whilst it's under 50p. Bought in at the beginning of June at 40.5, and some more now at 49p. It makes up just under 2% of my portfolio now.
Correction Newboy, 1 sticky troll. See my post from yesterday posted again below. No reason for 1 person to post from 2 accounts other than to mislead. It's actually only 1 guy Nige, Pomander and Dolphin5 is 1 person posting from 2 accounts. He got exposed on the 23rd March and retired the Dolphin5 account for a week or so, presumably to let it lay low for a while. He seems to use the Pom account to blast the company and its relationship with W2T, and the Dolphin5 account to try and highlight audit/compliance shortfalls, oh and feigning being insulted of course. A proper and decent person, interested in investing in this company, would address their concerns to the company or their advisers directly, and post back their responses here. If the responses weren't to his taste, then he'd stop looking at this company and find another. This however is the behavior of someone who feels he's been wronged by someone or something related to this company, or is an extremely persistent deramper. He even answers his own questions and backs up own answers, see 2nd April and yesterday, posting in the same string. Needless to say, this can only ever be viewed as a willful attempt to mislead and so both accounts should be ignored.
It's actually only 1 guy Nige, Pomander and Dolphin5 is 1 person posting from 2 accounts. He got exposed on the 23rd March and retired the Dolphin5 account for a week or so, presumably to let it lay low for a while. He seems to use the Pom account to blast the company and its relationship with W2T, and the Dolphin5 account to try and highlight audit/compliance shortfalls, oh and feigning being insulted of course. A proper and decent person, interested in investing in this company, would address their concerns to the company or their advisers directly, and post back their responses here. If the responses weren't to his taste, then he'd stop looking at this company and find another. This however is the behavior of someone who feels he's been wronged by someone or something related to this company, or is an extremely persistent deramper. He even answers his own questions and backs up own answers, see 2nd April and yesterday, posting in the same string. Needless to say, this can only ever be viewed as a willful attempt to mislead and so both accounts should be ignored.
Was Pom the one who was caught posting from two different accounts a couple of weeks ago?
I'm a new investor, have been following for a few weeks but finally bought in this morning with a couple of grand's worth. I'm looking forward to the roller coaster ride! I've been building up a few positions in micro Biotech and Pharma companies over the last few months. IMM, MTFB, C4XD and now N4P. Have mostly been a value/divi investor, but I fancy some growth plays too now and this looks like another good bet. GLA!
I thought when the institutions want to buy in, they talk to the company's broker and sort out a placing, usually at discount. So then the share price falls down to placing price and the private investors get @#�&ed over. Not fair, but it does seem to happen. The bod have to agree that first though, so might not happen here.
Indeed, up almost 100% from the intraday low 2 weeks ago!
Been looking at Motif for a few weeks now. Bought in this morning at 34.94.
I just bought in at 114.999
The general consensus on the IMM board is that it will hit �3-6 on positive headline results. Currently it's 160p, so I guess he means �4.
Yes, IMM have promised Lupuzor phase III trial results out in middle of April, so 2 weeks away. A drug at phase III completion must be at least 5 years ahead of one doing mouse treatments. And inhibitor style treatments have a long history of failure. Only one has passed, Benlysta, the current standard of care. And after quite a few years as the only drug in the marketplace for the 5m lupus sufferers, it still hasn't managed to get near blockbuster status as its side affects barely outway it's advantages. There is a great link about this I'll try and dig out. Lupuzor isn't an inhibitor. As such it has shown a perfect safety record in all previous trials and an improved effectiveness on Benlysta at phase IIb comparison. I would play close attention to their results.